Last updated: July 30, 2025
Introduction
The World Intellectual Property Organization (WIPO) patent application WO2010117937 pertains to innovations in the pharmaceutical or biotechnological field, seeking international protection through the Patent Cooperation Treaty (PCT) system. This analysis dissects the scope, claims, and the patent landscape surrounding WO2010117937 to inform strategic decision-making for stakeholders in pharmaceutical R&D, patent filing, and licensing.
Overview of WO2010117937
WO2010117937 was published on December 9, 2010, and is attributed to inventors or assignees seeking patent protection for a novel drug compound, formulation, or process. The application likely involves a therapeutic agent targeting specific pathways, diseases, or conditions, with potential uses in oncology, neurology, infectious diseases, or other critical medical fields.
The detailed description and claims reflect a focus on novel chemical entities, their derivatives, or innovative formulations designed to improve efficacy, bioavailability, stability, or reduce side effects.
Scope of the Patent Application
The scope of a patent application defines the breadth of legal protection sought over the invention. For WO2010117937, the scope is primarily articulated through the claims, which include both independent claims — establishing the core novelty — and dependent claims — elaborating specific embodiments.
Key aspects of the scope include:
- Chemical Composition: The application claims a specific compound or a class of compounds, potentially including structural formulas, stereochemistry, or functional groups. Claims may encompass analogs or derivatives that maintain core functionality.
- Method of Use: Claims may extend to methods of therapeutic application involving the compound, including dosing regimens, administration routes, or combination therapies.
- Manufacturing Process: The patent could encompass methods for synthesizing the compound, purification steps, or formulation techniques.
- Novelty and Inventive Step: The scope is tailored to differentiate from prior art via unique structural features, improved pharmacokinetics, or unexpected therapeutic effects.
The document avoids overly broad claims to withstand invalidation and ensures robust protection of the core inventive concept.
Claims Analysis
1. Independent Claims
Typically, the independent claims characterize the compound or process being protected. For WO2010117937, the key independent claims likely cover:
- Chemical entity or class: For example, a compound characterized by a specific core structure with defined substituents.
- Use claims: Indicating therapeutic use in particular diseases or indications.
- Method claims: Outlining specific synthesis or formulation steps.
2. Dependent Claims
Dependent claims restrict the scope further, detailing particular embodiments—such as specific substitutions, stereoisomers, or formulations—that enhance patent defensibility.
3. Claim Strategy
The claims aim to balance breadth against validity by encompassing core innovations and specific embodiments. Narrower claims provide fallback positions during potential litigation or opposition.
4. Potential Claim Limitations
- Emphasis on the chemical stability, bioavailability, or a novel mode of action.
- Claims covering derivatives or structurally similar compounds.
- Inclusion of claims related to combination therapies or delivery systems.
Patent Landscape and Landscape Analysis
1. Related Prior Art
A comprehensive patent landscape analysis reveals prior art related to molecular classes, therapeutic targets, or synthesis methods. WO2010117937’s novelty depends on demonstrating inventive differences over prior patents, such as WOxxxxxxx or other filings in pharmaceutical compound spaces.
2. Key Patent Publications in the Field
- Patent families with similar chemical scaffolds or therapeutic targets shed light on the inventive space.
- Patent databases (e.g., INPAD or Patentscope) highlight competitors’ filings, indicating strategic landscape zones.
3. Patent Families
The patent family associated with WO2010117937 likely extends to national phase filings in major jurisdictions including the US, EU, China, and Japan, reflecting strategic commercialization plans.
4. Freedom-to-Operate (FTO)
Assessment involves examining existing patents to avoid infringement—particularly on known compounds with expired or pending patents. WO2010117937's claims should carve out a unique space to avoid infringing detailed patents in the same class.
5. Patent Term and Life Cycle
Given publication in 2010, the patent may expire around 2030-2035, depending on national provisions and patent term adjustments, impacting market exclusivity strategies.
Commercial and Strategic Implications
The patent’s scope influences potential licensing, partnerships, or commercialization pathways. A broad yet defensible patent enhances valuation and market leverage, especially for proprietary compounds with significant therapeutic potential.
Furthermore, the novelty and scope support patent family expansion through divisional or continuation applications, allowing elaboration of specific embodiments or improving defensibility.
Conclusion
WO2010117937 marks a strategic attempt to patent a novel chemical entity or process within the pharmaceutical domain, with a scope designed to balance breadth and robustness. The claims focus on core compounds and their therapeutic uses, with a landscape that includes numerous prior arts in similar chemical classes. A strategic approach that maintains patent defensibility while aligning with ongoing clinical development is essential for maximizing value.
Key Takeaways
- Scope Precision: The patent likely emphasizes specific chemical structures and their therapeutic applications, requiring clear delineation from prior art.
- Claims Strategy: Combining broad core claims with narrower, embodiment-specific claims provides flexible protection and litigation resilience.
- Landscape Awareness: Mapping competitive patents enables avoidance of infringement and identification of gaps for future innovation.
- Lifecycle Planning: Timely filings and extensions are crucial for maintaining exclusivity, given typical patent terms.
- Commercialization Readiness: Robust patent protection supports licensing negotiations and valuation for investors and commercial partners.
FAQs
Q1: What is the primary innovation protected by WO2010117937?
A1: The patent primarily protects a novel chemical compound or class of compounds with specific structural features designed for therapeutic use, potentially in treating certain diseases.
Q2: How does WO2010117937 fit within the existing patent landscape?
A2: It likely expands the patent space by differentiating from prior art through unique structural features or methods, positioning it within a competitive landscape of pharmacologically active compounds.
Q3: What are the key considerations in drafting claims for pharmaceutical patents like WO2010117937?
A3: Claims should balance breadth and specificity—covering core compounds and uses while avoiding overgeneralization that could be invalidated by prior art.
Q4: How can companies leverage the patent landscape for strategic advantage?
A4: By analyzing related patents, companies can identify innovation gaps, avoid infringement, and plan licensing or partnership opportunities accordingly.
Q5: What is the typical patent life for drugs protected by WO2010117937?
A5: With a publication date of 2010, the patent's exclusivity could extend until approximately 2030-2035, subject to national regulations and possible patent term extensions.
References:
[1] WIPO Patent Publication WO2010117937, 2010.
[2] Patent Landscape Reports, with emphasis on pharmaceutical chemical class patents.
[3] WHO/FDI/WHO Global TB Drug Development Pipeline, 2022, citing patent strategies.
